CDK1 and glioblastoma: To test these hypotheses, we first measured the half-lives of CDK1 mRNA in GBM cell lines with upregulated or downregulated SRSF9 expression, and found that SRSF9 has no significant impact on CDK1 mRNA stability (Fig. 7A, B).